Summary
The Indian Pharmaceutical Alliance (IPA) states that tariffs alone are insufficient to establish sustainable generic drug manufacturing in the US, advocating for broader reforms. India currently supplies nearly 50% of generic medicines to the United States, and the IPA emphasizes the need to address upstream buying groups and delayed generic competition.